secwatch.observer — SEC 8-K summary
======================================

Issuer:     VOLITIONRX LTD (VNRX)
CIK:        0000093314
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001477932-23-008448
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VolitionRx reports 185% revenue increase in 9M 2023; FDA 510(k) pathway for NETs
--------------------------------------------------------------------------------

- Revenue for first nine months 2023 was $531k, up 185% YoY; Nu.Q Vet Cancer Test revenue grew ~5x.
- Cash and equivalents $10.8M as of Sep 30, 2023, roughly flat vs year-end 2022.
- Post-quarter: Walloon funding approved for ~$6M; expects $13M milestone payments from Heska.
- FDA agreed to traditional 510(k) pathway for Nu.Q NETs test following Q-Sub process.
- Launched Nu.Q Vet Test in UK/Ireland via NationWide Laboratories and Veterinary Pathology Group.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/93314/000147793223008448/0001477932-23-008448-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/93314/000147793223008448/vnrx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-23-008448

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer